Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Healthineers scores big in the third quarter
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
